|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic testing services. |
|---|---|
| Transferring Party | HemoCue, a Sweden-based manufacturer of point-of-care testing products and technology. |
| Sector | Diagnostics |
| Date | February 5, 2007 |
| Analysis Puts Quest into the growing near patient testing market and leverage HemoCue's international presence. HemoCue's handheld systems are used in physicians' offices, blood banks, hospitals, diabetes clinics, and public health clinics for anemia screening. The measurement of hemoglobin is important for patients being treated by transfusion, or undergoing dialysis or chemotherapy, where instant test results can lead to immediate treatment decisions. HemoCue was owned by private equity firm EQT II B.V. Deal Value -- $420m on revenue of $90m (4.7x). | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |